Mercury Laboratories Limited (BOM:538964)

India flag India · Delayed Price · Currency is INR
750.55
-8.45 (-1.11%)
At close: Jun 16, 2026
Market Cap900.66M -10.7%
Revenue (ttm)759.37M +1.1%
Net Income48.34M +53.7%
EPS40.28 +53.7%
Shares Out 1.20M
PE Ratio18.63
Forward PEn/a
Dividend3.50 (0.47%)
Ex-Dividend DateSep 21, 2026
Volume136
Open769.10
Previous Close759.00
Day's Range740.10 - 769.20
52-Week Range620.55 - 976.00
Beta0.41
AnalystsStrong Buy
Price Targetn/a
Earnings DateMay 29, 2026

About Mercury Laboratories

Mercury Laboratories Limited engages in manufacturing, selling, exporting, and dealing in various pharmaceutical drugs and medicines for mother and child healthcare in India and internationally. The company offers analgesic, anti-inflammatory, anti-pyretic, anthelmintic, antibiotic, anti-coagulant, anti-platelet, bleeding agent, anti-fungal, anti-hypertensive, anti-malarial, cardiovascular system, central nervous system, eye, gastro-intestinal system, hypoglycemic/anti-diabetic, multivitamin, protein supplement, respiratory system, anti-allergi... [Read more]

Industry Pharmaceutical Preparations
Founded 1962
Employees 503
Stock Exchange Bombay Stock Exchange
Ticker Symbol 538964
Full Company Profile

Financial Performance

In fiscal year 2026, Mercury Laboratories's revenue was 759.37 million, an increase of 1.11% compared to the previous year's 751.01 million. Earnings were 48.34 million, an increase of 53.71%.

Financial Statements